Filing Flows › Lyell Immunopharma (LYEL) › Q1 2026
Lyell Immunopharma (LYEL) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Lyell Immunopharma (LYEL) reported revenue of $2K for the first quarter 2026 (Q1 2026), -71% from a year earlier and -67% from the quarter before.
Lyell Immunopharma, Q1 2026: revenue $2K (-71% year over year), net loss $24.2M, operating cash flow −$38.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2K | -67% | -71% |
| Operating profit | −$44.3M | — | — |
| Net earnings | −$24.2M | — | — |
| Operating cash flow | −$38.5M | — | — |
What changed
Revenue was $2K in Q1 2026, down 71% year over year and down 67% from the previous quarter.
Operating costs exceeded revenue by $44.3M, an operating margin of -2213050.0%. Total costs fell 23% while revenue fell 71%. The quarter ended with a net loss of $24.2M, narrower than the previous quarter's $140.7M loss. Non-operating items added $20.1M, -83% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$38.5M. Non-cash charges added back $2.3M of depreciation and amortization and $4.3M of share-based compensation. Working capital and other items used $21.0M. Capital expenditures of $89K exceeded it, leaving free cash flow of −$38.6M.
Questions
What was Lyell Immunopharma's revenue in the first quarter 2026?
Lyell Immunopharma (LYEL) reported revenue of $2K for the first quarter 2026 (Q1 2026), -71% from a year earlier and -67% from the quarter before.
Source: Lyell Immunopharma 10-Q on SEC EDGAR.